Hogy Medical Co (3593) AI Stock Analysis

• Market Cap: $55.17B
• Dividend Yield: 1.94%
• Average Volume (3M): 52.98K
• Price to Earnings (P/E): 57.5
• Beta (1Y): 0.39
• Revenue Growth: 0.10%
• EPS Growth: -41.21%
• Country: JP
• Employees: 1,408
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 67.94
• Shares Outstanding: 22,535,463
• 10 Day Avg. Volume: 63,970
• 30 Day Avg. Volume: 52,983
• PEG Ratio: -1.32
• Price to Book (P/B): 1.27
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 13.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $3,697.82
• Price Target Upside: -4.94% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 63 Neutral
• Price Target: ―

Hogy Medical Co presents a mixed outlook. Financial performance is strong due to low leverage and consistent cash flow. However, technical analysis shows bearish signs with downward momentum. Valuation is a concern with a high P/E ratio, though the dividend yield provides some support.

Hogy Medical Co Business Overview & Revenue Model

Company Description

Hogy Medical Co (3593) is a Japanese company that specializes in the production and distribution of medical supplies and equipment. The company operates primarily within the healthcare sector, offering a wide range of products including surgical kits, medical gowns, and other disposable medical products. Hogy Medical Co is dedicated to improving healthcare efficiency and safety through its high-quality and innovative solutions.

How the Company Makes Money

Hogy Medical Co makes money by manufacturing and selling medical supplies and equipment to hospitals, clinics, and other healthcare facilities. The company's revenue model is primarily based on the sale of disposable medical products, which are essential for maintaining hygiene and safety standards in medical environments. Key revenue streams include direct sales of surgical kits and disposable medical clothing, as well as long-term supply contracts with healthcare institutions. Hogy Medical Co might also engage in partnerships with medical distributors to expand its market reach. The company's financial performance is influenced by factors such as healthcare industry demand, regulatory changes, and advancements in medical technology.

Hogy Medical Co Financial Statement Overview

Summary

Hogy Medical Co demonstrates financial stability with a strong balance sheet and consistent cash flow generation. Despite some decline in profitability margins, the company maintains solid revenue and gross margin performance. The low leverage and high equity ratio contribute to financial resilience.

Income Statement

Hogy Medical Co shows solid revenue stability with a slight increase in revenue over the years. The Gross Profit Margin is consistently strong, indicating effective cost management. However, there's a notable decline in Net Profit Margin and EBIT Margin in the latest year compared to prior periods, suggesting increased operational costs or lower pricing power. The EBITDA Margin remains robust, highlighting strong earnings before accounting for interest, taxes, depreciation, and amortization.

Balance Sheet

The company maintains a healthy balance sheet with a very low Debt-to-Equity Ratio, indicating low financial leverage. The Return on Equity has seen some fluctuation but remains positive, reflecting efficient use of equity capital. The Equity Ratio is high, signifying strong financing through equity and low reliance on debt, which provides financial stability.

Cash Flow

Hogy Medical Co exhibits strong cash flow with consistent Free Cash Flow generation and growth in Operating Cash Flow. The Free Cash Flow to Net Income Ratio indicates solid cash generation relative to net income, despite some variability in Free Cash Flow growth over the years. The Operating Cash Flow to Net Income Ratio showcases the company's ability to convert net income into cash effectively.

Breakdown
Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement		Total Revenue
39.14B	39.10B	38.98B	36.78B	36.50B
	Gross Profit
12.62B	12.49B	15.74B	15.42B	15.33B
	EBIT
3.46B	4.17B	6.63B	6.13B	5.63B
	EBITDA
8.75B	10.71B	10.25B	10.25B	10.18B
	Net Income Common Stockholders
1.52B	2.80B	4.32B	4.37B	4.96B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
22.00B	19.42B	18.86B	14.36B	20.55B
	Total Assets
97.89B	100.04B	102.18B	98.97B	105.64B
	Total Debt
13.67B	5.82B	8.89B	10.00B	330.00M
	Net Debt
-8.34B	-13.60B	-9.97B	-4.36B	-20.22B
	Total Liabilities
23.56B	13.92B	18.50B	18.97B	9.69B
	Stockholders Equity
74.32B	86.11B	83.61B	79.96B	95.88B
Cash Flow		Free Cash Flow
6.53B	4.32B	7.78B	5.30B	-686.00M
	Operating Cash Flow
11.76B	7.12B	9.18B	8.50B	6.85B
	Investing Cash Flow
-4.12B	-3.26B	-1.95B	-3.81B	-6.95B
	Financing Cash Flow
-5.46B	-3.89B	-3.14B	-11.05B	-2.50B

Hogy Medical Co Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3890.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3593, the sentiment is Negative. The current price of 3890 is below the 20-day moving average (MA) of 3914.00, below the 50-day MA of 4128.40, and below the 200-day MA of 4518.69, indicating a bearish trend. The MACD of -91.52 indicates Negative momentum. The RSI at 44.95 is Neutral, neither overbought nor oversold. The STOCH value of 57.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3593.

Hogy Medical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7817	80 Outperform	$139.68B	16.25	6.55%	3.60%	2.42%	-13.12%
7730	76 Outperform	¥118.12B	19.57		3.25%	11.54%	-8.30%
3154	72 Outperform	¥21.64B	16.03		2.16%	14.12%	56.92%
7716	66 Neutral	€162.24B	28.37	4.78%	2.74%	20.53%	-75.16%
3593	63 Neutral	$55.17B	57.54	1.87%	1.94%	0.10%	-41.21%
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
7702	53 Neutral	¥10.31B	116.15		4.03%	6.83%	―

Hogy Medical Co Corporate Events

Hogy Medical’s Board Opposes Shareholder Proposal on Director Elections

Hogy Medical Co., Ltd.’s Board of Directors has decided to oppose a shareholder proposal from Nippon Active Value Fund plc regarding the election of three directors at the upcoming Annual General Meeting. The Board believes that its current composition, which includes a Nomination Committee to ensure independence and accountability, is optimal for implementing its medium-term management plan aimed at sustainable growth and enhanced corporate governance.

The most recent analyst rating on (JP:3593) stock is a Hold with a Yen3700.00 price target. To see the full list of analyst forecasts on Hogy Medical Co stock, see the JP:3593 Stock Forecast page.

Hogy Medical Co. Announces Leadership Changes to Strengthen Management

Hogy Medical Co., Ltd. announced a significant change in its leadership structure, with Taisuke Fujita being appointed as the new Representative Director and Vice President, effective June 20, 2025. This strategic move aims to strengthen the company’s management framework, potentially impacting its operational efficiency and market positioning. Additionally, the company will see the resignation of two outside directors, Kiyoshi Uesugi and Yuta Kinose, on the same date.

The most recent analyst rating on (JP:3593) stock is a Hold with a Yen3700.00 price target. To see the full list of analyst forecasts on Hogy Medical Co stock, see the JP:3593 Stock Forecast page.

Hogy Medical Co. Reports Decline in Profits Despite Stable Sales

Hogy Medical Co., Ltd. reported its consolidated financial results for the fiscal year ending March 31, 2025, showing a slight increase in net sales by 0.1% to ¥39,138 million. However, the company experienced a significant decline in profits, with operating profit down by 8.6% and profit attributable to owners of the parent down by 45.8%. Despite these challenges, the company maintained its dividend payments and forecasts a recovery in profits for the next fiscal year, indicating a strategic focus on improving financial performance.